

United States

# The Mortgage Analyst

Credit Strategy Research

## The correlation structure of agency MBS returns

### Year-over-year returns on MBS have been strong

2013 was a painful year for fixed income investors, and mortgage backed securities (MBS) experienced negative returns for the full year for the first time since 1994. The past twelve months (June 2013 to June 2014), however, have been better, with the MBS index returning 5.3% in nominal terms. After adjusting for low current funding costs, this represents a better than average (70<sup>th</sup> percentile) twelve-month return experience.

### Correlations of returns across TBA cohorts have increased

Prior to the mortgage crisis period, realized returns across different TBA cohorts were typically highly correlated, broadly moving together on macro-market forces like rising/falling rates or rising/falling volatilities. However, during the crisis period, correlations of returns across TBAs declined. Targeted Federal Reserve purchases of selected MBS cohorts, HARP policy changes affecting only a subset of products and coupons, and spikes in delinquent loan buyouts were among the events which introduced idiosyncratic risks, causing the TBA cohorts to de-correlate. The decline in correlations made risk-management for MBS portfolios difficult during the crisis period, as typical hedge relationships failed to hold. However, evidence suggests that tighter correlations across TBA cohorts have recently been re-established. In 2013Q1, typical correlations in returns were below 45%, but over the past year correlations exceeded 80%.

### Over next 12-months, expect high correlations, low returns

We expect the factors generating **idiosyncratic** price moves during 2011-2013 – including monetary policy effects, HARP policy changes, and delinquent loan buyouts – to have relatively smaller impacts going forward, meaning correlations across cohorts will remain high. However, we expect the negative returns seen in 2013 to return over the next year, on rate moves up. To shorten duration, we like up-in-coupon for 30-year conventionals rather than moving down into 15-year TBAs.

#### Charles P. Himmelberg

(917) 343-3218 charles.himmelberg@gs.com  
Goldman, Sachs & Co.

#### Marty Young

(917) 343-3214 marty.young@gs.com  
Goldman, Sachs & Co.

#### Hui Shan

(212) 902-4447 hui.shan@gs.com  
Goldman, Sachs & Co.

#### Chris Henson

(801) 741-5755 chris.henson@gs.com  
Goldman, Sachs & Co.

#### Spencer Rogers

(801) 884-1104 spencer.rogers@gs.com  
Goldman, Sachs & Co.

This research is focused on investment themes across markets, industries and sectors. It does not attempt to distinguish between the prospects or performance of, or provide analysis of, individual companies within any industry or sector we describe. Investors should consider this research as only a single factor in making investment decisions. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to [www.gs.com/research/hedge.html](http://www.gs.com/research/hedge.html).

## MBS returns have been strong over past twelve months


The fixed income market in general and the mortgage backed securities (MBS) market in particular experienced a painful 2013, with MBS earning negative returns on the full year. But over the past twelve months (June 2013-June 2014), returns have been more benign. Exhibit 1 shows that the lagging twelve-month return on the MBS index has been 5.3%: just slightly below long-run average and a 43<sup>rd</sup> percentile return over history.

This recent mortgage performance looks even more impressive when measured as an excess return: MBS returns minus the Fed Funds rate. This excess return can be thought of as the return net of funding costs. Exhibit 2 shows that the year-over-year excess return is 5.2%, corresponding to a 70<sup>th</sup> percentile result over the 1997-2014 period.

These exhibits show the total returns for the broad MBS index (including 30-year and 15-year GNMA, FNMA and FHLMC pass-throughs, on a balance weighted basis), with total return capturing price changes, interest, and scheduled and unscheduled principal cash-flows. Of the 5.3% total return, 3.9% came from interest coupons, 1.1% from price appreciation, and the residual from principal amortization and prepayments.


Exhibits 1 and 2 suggest that MBS returns have “returned to normal”, after an unusually weak 2013H1. In the following sections, we look under the surface at the correlations across pairs of TBA cohorts (e.g., FNM30 3% vs. FNM30 5%, or FNM30 3% vs. GNM30 3%). We find that in that sense as well returns have re-normalized, with tight correlations in returns seen over the past year. We then ask whether we expect the normalized MBS performance to persist into the future. Our answer to the latter question is mixed: we expect the tight correlations across cohorts to persist, but, given our bearish view on rates we anticipate negative MBS returns to occur again over the next twelve months.

**Exhibit 1: Lagging year-over-year return on the MBS index is now positive**  
12-month agency MBS index total return



Source: Haver and Goldman Sachs Global Investment Research

**Exhibit 2: MBS excess returns (return net of Fed Funds) has been above average over past twelve month horizon**  
12-month agency MBS index total return – Fed Funds rate



Source: Haver and Goldman Sachs Global Investment Research

## MBS return correlations have risen on lower idiosyncratic risks

### MBS returns de-correlated in 2013, but correlations have returned

Exhibit 1 shows that 2013 was a trying time in aggregate for the MBS market, but in addition to the aggregate return volatility, there was increased turbulence under the surface of the market index. In most periods the different actively traded TBA cohorts have returns which are fairly tightly correlated with one another, with the returns all strongly driven by common risk factors such as rising/falling rates or increasing/declining volatilities. However during 2011-2013, correlations of returns across TBAs declined. Targeted Federal Reserve purchases of selected MBS cohorts, HARP policy changes affecting only a subset of products and coupons, and spikes in delinquent loan buyouts were among the events which introduced idiosyncratic risks, causing the TBA cohorts to de-correlate.


The decline in correlations made risk-management for MBS portfolios challenging during the 2011-2013 period, as typical hedge relationships failed to hold. However, evidence suggests that correlations across assets have more recently been re-established. Exhibit 3 shows the median cross-correlation across the 18 largest Fannie Mae 30-year, Fannie Mae 15-year, and Ginnie Mae 30-year cohorts over time. At each point in time, the pairwise correlations in returns over the subsequent year are calculated across all pairs of cohorts, and the median is used to summarize the typical correlation across all the pairs.

During the 2000-2007 period the typical pairwise correlation was 89%, indicating that hedging or relative value trading strategies involving being long one cohort and short another had relatively limited basis risk. During 2011-2013 correlations declined and by 2013 the typical correlation across pairs of TBA cohorts was only 42%. However, correlations have reemerged, and over the past 12 months the correlation in returns across cohorts was 83%, close to pre-crisis average levels.

As one example of this change in correlation structure, Exhibit 4 shows the weekly returns over the April 2012-April 2013 period for the FNM30 3.5% and 5.0% cohorts; the  $R^2$  was 20%. Over the past year (June 2013-June 2014), the same pair of cohorts had a 62%  $R^2$  (Exhibit 5).

### Exhibit 3: TBA cohorts de-correlated during 2011-2013, but correlations have since returned to normal levels


Median cross-correlation in returns across 18 largest TBA cohorts



Source: Yield Book and Goldman Sachs Global Investment Research

**Exhibit 4: Correlations in returns across TBA cohorts was weak during 2011-2013...**


5-day returns, FNM30 3.5 vs. FNM30 5.0, Apr 2012-Apr 2013



Source: Goldman Sachs Global Investment Research

**Exhibit 5: ... but correlations have increased over the past year.**

5-day returns, FNM30 3.5 vs. FNM30 5.0, Jun 2013-Jun 2014




Source: Goldman Sachs Global Investment Research

**Principal component analysis confirms correlations restored in 2014**

A similar conclusion to the one described above – that correlations declined in 2011-2013, but have since returned to more normal levels – is obtained if the cross-section of TBA cohort returns is analyzed by a rolling 52-week principal components analysis. Exhibit 4 shows that the first principal component across the FNM30/FNM15/GNM30 TBA cohorts typically explains >90% of variance. In 2013 the percentage fell below 60%, but it has since returned to 93%. This large percentage of MBS return variance explained by a single factor is high compared to results seen when decomposing returns across global equity or global CDS indices, where the first principal factor explains 60%-75% of variance (see “The role of common risk factors across uncommon asset markets”, *Global Economics Weekly*, April 9, 2014). Not surprisingly, the first principal component of MBS returns is highly correlated with interest rates; as of June 2014, the correlation between 10-year Treasury yields and the first principal component was 95%.

**Exhibit 6: The first principal component of MBS returns explains 93% of recent cross-cohort covariance, vs. 58% in 2013**

Percentage variance explained by first principal component of returns on 18 largest TBA cohorts



Source: Yield Book and Goldman Sachs Global Investment Research

## Recent returns show strong performance up-in-coupon

The statement that returns across TBA cohorts have again become correlated does not imply that returns on all cohorts are equal, only that the returns generally move in consistent directions in most periods. Exhibit 7 shows recent historical returns across different product and coupon cohorts. Over the past twelve months, returns were positive across all cohorts, but lower for 15-year than for 30-year MBS. Over the past one month horizon, high coupon cohorts out-performed lower coupon cohorts, as the 5-year Treasury rate sold off by 10-15 bp over the month. The out-performance of higher coupon cohorts on an unhedged basis was, in a sense, predictable given the rate movements. This greater predictability of relative returns allows for cleaner hedging and relative value trading strategies than was possible to achieve during 2011-2013.

**Exhibit 7: Over the past month returns were highest in the high coupon 30-year cohorts**  
Year-over-year and month-over-month total unhedged returns, agency MBS, as of 6/24/2014

Product	Coupon	Total Return	
		YoY	MoM
FNMA15	2.0	4.7%	-0.1%
FNMA15	2.5	4.5%	0.0%
FNMA15	3.0	3.9%	-0.1%
FNMA15	3.5	4.4%	0.2%
FNMA15	4.0	2.7%	-0.1%
FNMA15	4.5	1.6%	-0.1%
FNMA15	5.0	0.6%	0.3%
FNMA15	5.5	2.4%	0.5%
FNMA30	2.5	6.2%	0.0%
FNMA30	3.0	5.4%	0.0%
FNMA30	3.5	5.7%	0.0%
FNMA30	4.0	5.4%	0.3%
FNMA30	4.5	5.0%	0.3%
FNMA30	5.0	5.4%	0.6%
FNMA30	5.5	4.9%	0.6%
FNMA30	6.0	5.0%	0.6%
GNMA30	2.5	5.4%	-0.1%
GNMA30	3.0	6.7%	0.3%
GNMA30	3.5	6.1%	0.0%
GNMA30	4.0	6.0%	0.2%
GNMA30	4.5	5.8%	0.2%
GNMA30	5.0	4.7%	0.1%
GNMA30	5.5	4.5%	0.4%

Source: Yield Book and Goldman Sachs Global Investment Research

## Expect high correlations to remain, but for returns to turn negative

### Lower idiosyncratic risk, high common risk

The exhibits above suggest that in 2013 MBS returns were atypical of long-run history, but in 2014 MBS performance returned toward the long-run average. 2013 was atypical in at least two respects: aggregate index returns were abnormally low, and the correlations across TBA cohorts were also low. Should we expect these trends seen in 2014H1 to persist into the future? Our response to this question is mixed: we expect the correlations across TBA cohorts to remain high, but we also expect returns over the next twelve months to turn negative again.

The abnormally low correlations across cohorts seen during the 2011-2013 period were driven by events and market forces that disproportionately impacted a limited number of cohorts. For example, the tightening of mortgage spreads around the inception of QE3 and the subsequent widening that occurred during the taper tantrum period affected all cohorts, but impacted the current coupon 30-year cohorts more than the more off-the-run portions of the coupon stack. Our models suggest that much – though not all – of the impact of the QE program has already been unwound, so that mortgage spreads look close to what they looked like pre-QE after controlling for factors like rate volatility and swap spreads (see “MBS basis tightening consistent with declining rate volatility”, *The Mortgage Analyst*, May 16, 2014). Our central scenario calls for modest spread widening over a medium-term horizon as QE tapering continues, but do not expect the adjustment to generate large discontinuous price changes to a small number of cohorts.

Similarly, we do not expect policy changes to dramatically change the prepayment landscape over the next twelve months. A change to loan level pricing adjustments is expected, and that would have disproportionate impacts on certain selected cohorts. Our research suggests, for example, that the change to LLPAs proposed by former FHFA Director DeMarco in December 2013 – a change which was subsequently postponed by incoming Director Watt – would have the largest impact on spreads of the FNM30 5.0 coupon, vs. other portions of the coupon stack (see “Loan-Level Price Adjustments: FHFA’s next move”, *The Mortgage Analyst*, June 12, 2014). However, we estimate that the pricing impact will be smaller than that which was seen with earlier policy changes such as introduction of the HARP 2.0 program.

The potential impact of policy changes has been diminished by the prepayment burnout of seasoned pools. The most responsive borrowers already prepaid in 2013, so it would require a relatively large change to mortgage rates and points to induce a significant shock to realized prepayments in 2014. The impact of a given policy change on prepayments will decline over time given our expectation of rising rates going forward.

However, while we see future idiosyncratic risk to TBAs as lower than was experienced during the 2011-2013 period, our expectation of rising rates creates common risk for the entire MBS complex. Our interest rates strategists have recommended a short position in 3-year US Treasuries, viewing the risk premium there as underpriced relative to our central expectation of robust economic growth. On this yield curve forecast, 10-year Treasuries would be negative over a twelve-month horizon (see “Sustained growth and policy easing: OW equities and UW bonds”, *GOAL: Asset Allocation Update*, June 23, 2014).

The duration of the MBS index is shorter than the duration of 10-year Treasuries, and the coupon of MBS is higher, and these factors would lead to higher returns for mortgages. On the other hand, mortgages are negatively convex, and we anticipate spread widening over the next twelve months, and these considerations would hurt mortgage returns. All in, our unhedged total return expectation for the mortgage index over the next twelve months is negative.

### **Shorten duration by moving up-in-coupon, not down-in-maturity**

If interest rates move as we project, all mortgage bonds would be affected but shorter-duration assets would be impacted less. We have written in the past that 15-year MBS represents an expensive strategy for shortening duration (see “Risks and returns of 15-year vs. 30-year MBS”, *The Mortgage Analyst*, April 4, 2014, and “15-year mortgages: rich to 30-year?”, *The Mortgage Analyst*, September 20, 2013). 15-year mortgages have cheapened some vs. 30-year but we still view new 15-year TBA as expensive on an option-adjusted basis. Alternative expressions of a short-duration positioning that appear cheaper than 15-year TBA include up-in-coupon 30-year conventionals (e.g., 4.5% coupon), seasoned 15-year collateral, or structured product.

**Marty Young**



# Disclosure Appendix

## Reg AC

We, Charles P. Himmelberg, Marty Young, Hui Shan, Chris Henson and Spencer Rogers, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

## Disclosures

### Regulatory disclosures

#### Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs usually makes a market in fixed income securities of issuers discussed in this report and usually deals as a principal in these securities.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage. **Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director, advisory board member or employee of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman, Sachs & Co. and therefore may not be subject to NASD Rule 2711/NYSE Rules 472 restrictions on communications with subject company, public appearances and trading securities held by the analysts.

#### Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. **Australia:** Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of the Global Investment Research Division of Goldman Sachs Australia may attend site visits and other meetings hosted by the issuers the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. **Brazil:** Disclosure information in relation to CVM Instruction 483 is available at <http://www.gs.com/worldwide/brazil/area/gir/index.html>. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 16 of CVM Instruction 483, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. **Canada:** Goldman Sachs Canada Inc. is an affiliate of The Goldman Sachs Group Inc. and therefore is included in the company specific disclosures relating to Goldman Sachs (as defined above). Goldman Sachs Canada Inc. has approved of, and agreed to take responsibility for, this research report in Canada if and to the extent that Goldman Sachs Canada Inc. disseminates this research report to its clients. **Hong Kong:** Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. **India:** Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited. **Japan:** See below. **Korea:** Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. **New Zealand:** Goldman Sachs New Zealand Limited and its affiliates are neither "registered banks" nor "deposit takers" (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for "wholesale clients" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. **Russia:** Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. **Singapore:** Further information on the covered companies referred to in this research may be obtained from Goldman Sachs (Singapore) Pte. (Company Number: 198602165W). **Taiwan:** This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. **United Kingdom:** Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

**European Union:** Disclosure information in relation to Article 4 (1) (d) and Article 6 (2) of the European Commission Directive 2003/126/EC is available at <http://www.gs.com/disclosures/europeanpolicy.html> which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

**Japan:** Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan and Type II Financial Instruments Firms Association. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

### Ratings, coverage groups and views and related definitions

Credit Research assigns ratings to designated on-the-run ("OTR") debt securities of issuing companies. **Definitions of Ratings:** **OP = Outperform.** We expect the total return to outperform the median total return for the analyst's coverage group over the next 6 months. **IL = In-Line.** We expect the total return to perform in line with the median total return for the analyst's coverage group over the next 6 months. **U = Underperform.** We expect the total return to underperform the median total return for the analyst's coverage group over the next 6 months.

**NR = Not Rated.** The investment rating, if any, has been removed pursuant to Goldman Sachs policy when to Goldman Sachs is acting in an advisory capacity in a merger or strategic transaction involving this company and in certain other circumstances. **NC = Not Covered.** Goldman Sachs does not cover this company. **RS = Rating Suspended.** Goldman Sachs Research has suspended the investment rating for this credit, because there is not a sufficient fundamental basis for determining, or there are legal, regulatory or policy constraints around publishing, an



investment rating. The previous investment rating is no longer in effect for this credit and should not be relied upon. **CS = Coverage Suspended.** Goldman Sachs has suspended coverage of this company. **NA = Not Available or Not Applicable.** The information is not available for display or is not applicable.

**Coverage views:** The coverage view represents each analyst's or analyst team's investment outlook on his/her/their coverage group(s). The coverage view will consist of one of the following designations: **Attractive (A).** The investment outlook over the following 6 months is favorable relative to the coverage group's historical fundamentals and/or valuation. **Neutral (N).** The investment outlook over the following 6 months is neutral relative to the coverage group's historical fundamentals and/or valuation. **Cautious (C).** The investment outlook over the following 6 months is unfavorable relative to the coverage group's historical fundamentals and/or valuation.

## Global product; distributing entities

The Global Investment Research Division of Goldman Sachs produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce equity research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; in Canada by either Goldman Sachs Canada Inc. or Goldman, Sachs & Co.; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman, Sachs & Co. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom and European Union.

**European Union:** Goldman Sachs International authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority, has approved this research in connection with its distribution in the European Union and United Kingdom; Goldman Sachs AG and Goldman Sachs International Zweigniederlassung Frankfurt, regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht, may also distribute research in Germany.

## General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by our Global Investment Research Division. Goldman, Sachs & Co., the United States broker dealer, is a member of SIPC (<http://www.sipc.org>).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and our proprietary trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, our proprietary trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

We and our affiliates, officers, directors, and employees, excluding equity and credit analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research.

Any trading recommendation in this research relating to a security or multiple securities within an industry or sector is reflective of the investment theme being discussed and is not a recommendation of any such security in isolation.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options disclosure documents which are available from Goldman Sachs sales representatives or at <http://www.theocc.com/about/publications/character-risks.jsp>. Transaction costs may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supplied upon request.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data available on a particular security, please contact your sales representative or go to <http://360.gs.com>.

Disclosure information is also available at <http://www.gs.com/research/hedge.html> or from Research Compliance, 200 West Street, New York, NY 10282.

© 2014 Goldman Sachs.

**No part of this material may be (i) copied, photocopied or duplicated in any form by any means or (ii) redistributed without the prior written consent of The Goldman Sachs Group, Inc.**